Analyst Ratings For NASDAQ:NTLA – Intellia Therapeutics (NASDAQ:NTLA)
Today, Wedbush reiterated its Outperform rating on NASDAQ:NTLA – Intellia Therapeutics (NASDAQ:NTLA) with a price target of $36.00.
Some recent analyst ratings include
- 5/18/2018-Wedbush Reiterated Rating of Outperform.
- 5/15/2018-Chardan Capital Upgrade from a “Neutral ➝ Buy” rating to a “” rating.
- 5/1/2018-Cann Reiterated Rating of Hold.
- 3/14/2018-Leerink Swann Reiterated Rating of Outperform.
- 3/8/2018-JMP Securities initiated coverage with a Mkt Outperform ➝ Outperform rating.
- 12/18/2017-Oppenheimer Reiterated Rating of Hold.
Recent Insider Trading Activity For NASDAQ:NTLA – Intellia Therapeutics (NASDAQ:NTLA)
NASDAQ:NTLA – Intellia Therapeutics (NASDAQ:NTLA) has insider ownership of 12.80% and institutional ownership of 54.70%.
- On 5/16/2018 Jean Francois Formela, Director, sold 6,686 with an average share price of $25.04 per share and the total transaction amounting to $167,417.44.
- On 5/14/2018 John M. Leonard, Insider, sold 8,400 with an average share price of $24.00 per share and the total transaction amounting to $201,600.00.
- On 3/20/2018 Jean Francois Formela, Director, sold 39,245 with an average share price of $23.87 per share and the total transaction amounting to $936,778.15.
- On 1/29/2018 Caribou Biosciences, Inc., Major Shareholder, sold 550,645 with an average share price of $26.78 per share and the total transaction amounting to $14,746,273.10.
- On 12/12/2017 Institutes For Biomed Novartis, Major Shareholder, sold 1,523,000 with an average share price of $18.30 per share and the total transaction amounting to $27,870,900.00.
- On 12/8/2017 Nessan Bermingham, CEO, sold 336,783 with an average share price of $20.78 per share and the total transaction amounting to $6,998,350.74.
- On 12/6/2017 Nessan Bermingham, CEO, sold 111,500 with an average share price of $20.34 per share and the total transaction amounting to $2,267,910.00.
Recent Trading Activity for NASDAQ:NTLA – Intellia Therapeutics (NASDAQ:NTLA)
Shares of NASDAQ:NTLA – Intellia Therapeutics closed the previous trading session at 25.57 down -0.41 1.58% with 26.0 shares trading hands.